3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
3
Unknown
1
Terminated
1
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Breast Neoplasms
2
Scleroderma, Localized
1
Radiation Injuries
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Pneumonia
1
Neurodermatitis
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lichen Planus
1
Leukemia
1
Keratoacanthoma
1
Keloid
1
Hemangioma
1
Granuloma Annulare
1
Dermoid Cyst
1
Dendritic Cell Sarcoma, Interdigitating
1
Cicatrix, Hypertrophic
1
Cancer Pain
1
Bone Neoplasms
1
Asthma
1
Arthritis, Rheumatoid
1
Alopecia Areata
1
Interventions
Gemcitabine
109
Paclitaxel
92
Carboplatin
79
pembrolizumab
75
Bevacizumab
75
Surveys and Questionnaires
70
Docetaxel
69
Cisplatin
67
Nivolumab
48
Exercise
48
Capecitabine
48
Cyclophosphamide
47
Sorafenib
43
Fluorouracil
43
Irinotecan
42
Pemetrexed
37
Albumin-Bound Paclitaxel
35
Radiotherapy
34
Dexamethasone
34
Blood Specimen Collection
34
Oxaliplatin
31
Leucovorin
31
Erlotinib Hydrochloride
31
trametinib
30
130-nm albumin-bound paclitaxel
29
Cetuximab
28
Therapeutics
26
Ipilimumab
26
Standard of Care
25
Methods
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasms
×
Adrenal Cortex Hormones
×
Clear all
NCT00848718
2019-11-12
MK-2206-003
Merck Sharp & Dohme LLC
Phase 1
Completed
77 enrolled
24 charts